Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose safety, tolerability, and pharmacokinetics study of ARM210 in healthy subjects
NL-OMON61127Phase 1Completed
- Sponsor
- RyCarma Therapeutics
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in arrhythmia comparing ARM210 with Placebo (2 arms). Primary endpoint: Primary endpoint(s). Started Feb 2024; status: completed.
02
Drugs
Surlorian
03
Conditions
arrhythmia
Beyond the preview
Go deeper on NL-OMON61127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61127.